Galapagos wins 2011 Scrip Award for Biotech Company of the Year

Mechelen, Belgium and London, UK; 4 November 2011 – Galapagos NV (Euronext: GLPG) announced that it won the prestigious Scrip Award for Biotech Company of the Year at last night’s ceremony in London.  The award recognizes the biotech company that has achieved the most in the 12-month period from June 2010 to May 2011.

The international jury, which consisted of sixteen industry experts, selected Galapagos as the Biotech Company of the Year from a group of six finalists.  The award criteria included: clinical progress, significant alliances and licensing deals, fund raising, strong management and applying a proprietary technology to address unmet medical needs. 

Galapagos was awarded the prize based on its transformation into a sustainably profitable biotech with a solid pipeline of novel mode-of-action drug candidates.  Galapagos has achieved this self reliance by successfully executing on a hybrid business model: combining profitable fee-for-service based service operations with an internal R&D division that has established six risk/reward sharing alliances with the world’s top pharma companies. 

“We are pleased to have won the 2011 Scrip Award for Biotech Company of the Year, which recognizes the impact of Galapagos’ proprietary technology and successful hybrid business model,” said Onno van de Stolpe, CEO of Galapagos.  “Furthermore, this award recognizes our transition to a more mature company with a full-fledged development pipeline.”

About the 2011 Scrip Awards

The 2011 Scrip Awards, hosted by Informa Healthcare — one of the world’s leading medical and scientific publishers — brings together hundreds of senior-level industry experts at one of the industry’s most prestigious contested awards ceremony, to highlight the achievements of pharmaceutical and biotech companies throughout the year.  More info

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing one of the largest pipelines in biotech, with seven programs in development and over 50 discovery programs.  Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to receive up to €2.8 billion in downstream milestones, plus royalties.  The Galapagos Group has about 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:


Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240


This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.